The Flare Phenomenon in a Patient with Advanced Gastric Cancer with Bone Metastases

Lee, Sangki; Shi, Hyejin; Sohn, Sungmin; Park, Sungrock; Wang, Sungho; Song, Jinkyung; Jang, Geundoo

doi:10.3904/kjm.2016.91.3.321

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…발적 현상은 치료 후 실제로는 골전이 병변이 치유되지만 뼈스캔에서는 오히려 새로운 골병변이 관찰되거나 기존 병변의 섭취 강도(uptake intensity)가 증가하는 현상을 말하며, 치료 시작 후 첫 12주 이내에 가장 많이 나타나고( 26 27 ) 이후 점진적으로 정상 뼈와 같은 섭취 상태로 호전되게 된다. 이 현상은 골병변이 치유되는 과정에서 일시적으로 증가된 골형성 반응이 뼈스캔에서 섭취 증가로 반영되는 것으로 여겨지며( 26 28 29 30 31 ), 실제 증가된 종양에 의한 골대사 증가로 인한 질병 진행과는 엄연히 다르다. 그러나 발적 현상에서 일시적이나마 종양의 범위가 증가된 것처럼 보이기 때문에, 성급하게 질병 진행으로 잘못 간주될 경우 치료가 조기에 중단될 위험이 있어 뼈스캔의 해석에 각별한 주의가 필요하다.…”

Section: 전이성 골병변 평가시 사전 고려 사항unclassified

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Jang,

Lee,

Park

et al. 2023

J Korean Soc Radiol

View full text Add to dashboard Cite

전립선암에서 뼈는 가장 흔한 전이병소이며, 전립선암의 질병 상태를 파악하고 치료 반응을 평가하기 위해서는 전이성 골병변의 평가가 필수적이다. 거세 저항성 전립선암은 남성호르몬을 거세 수치로 떨어뜨렸음에도 불구하고 암이 진행하는 상태를 의미하며, 이 상태에서는 원격 전이가 빈번하게 발생한다. 거세 저항성 전립선암의 치료 반응을 객관적으로 평가하기 위해 뼈스캔을 기반으로 한 Prostate Cancer Working Group 3 (이하 PCWG3) 가이드라인이 발표되었으나 실제 이를 쉽게 숙지하여 적용하기에는 어려운 점이 있다. 본 종설에서 PCWG3 가이드라인에 준한 거세 저항성 전립선암의 뼈스캔 기반 골병변 반응 평가를 위한 구체적인 영상 획득 방법 및 치료 반응 평가법을 소개하고자 한다.

show abstract

Section: 전이성 골병변 평가시 사전 고려 사항unclassified

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Jang,

Lee,

Park

et al. 2023

J Korean Soc Radiol

View full text Add to dashboard Cite

show abstract

“…The other case is about a 54-year-old male with baseline bone metastases from GC who showed an increased intensity at bone scan after three cycles of chemotherapy, despite an improvement in skeletal pain. Nevertheless, after additional three cycles of chemotherapy, the bone scan revealed a decrease in the intensity of the signal in the same areas [ 90 ].…”

Section: Clinical Management Of Metastatic Gastric Cancer Patients With Bone Involvementmentioning

confidence: 99%

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them

Petrillo

Giunta

Pappalardo

et al. 2021

JCM

View full text Add to dashboard Cite

Gastric cancer (GC) is the third cause of cancer-related death worldwide; the prognosis is poor especially in the case of metastatic disease. Liver, lymph nodes, peritoneum, and lung are the most frequent sites of metastases from GC; however, bone metastases from GC have been reported in the literature. Nevertheless, it is unclear how the metastatic sites may affect the prognosis. In particular, knowledge about the impact of bone metastases on GC patients’ outcome is scant, and this may be related to the rarity of bone lesions and/or their underestimation at the time of diagnosis. In fact, there is still a lack of specific recommendation for their detection at the diagnosis. Then, the majority of the evidences in this field came from retrospective analysis on very heterogeneous study populations. In this context, the aim of this narrative review is to delineate an overview about the evidences existing about bone metastases in GC patients, focusing on their incidence and biology, the prognostic role of bone involvement, and their possible implication in the treatment choice.

show abstract

The Flare Phenomenon in a Patient with Advanced Gastric Cancer with Bone Metastases

Cited by 2 publications

References 8 publications

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them

Contact Info

Product

Resources

About